KR102537340B1 - 베타-락타마제 억제제 화합물 - Google Patents

베타-락타마제 억제제 화합물 Download PDF

Info

Publication number
KR102537340B1
KR102537340B1 KR1020197010376A KR20197010376A KR102537340B1 KR 102537340 B1 KR102537340 B1 KR 102537340B1 KR 1020197010376 A KR1020197010376 A KR 1020197010376A KR 20197010376 A KR20197010376 A KR 20197010376A KR 102537340 B1 KR102537340 B1 KR 102537340B1
Authority
KR
South Korea
Prior art keywords
delete delete
alkyl
mmol
methyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197010376A
Other languages
English (en)
Korean (ko)
Other versions
KR20190043630A (ko
Inventor
그레고리 에스. 바사랍
자넬 코미타-프레보이어
토마스 프랑수아 두란드-레빌레
리즈 고티에
빌 모스
존 오'도넬
잔 로메로
루벤 토마시
제로엔 쿠네라 베레이젠
프란크 우
샤오윈 우
징 장
Original Assignee
엔타시스 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엔타시스 테라퓨틱스 리미티드 filed Critical 엔타시스 테라퓨틱스 리미티드
Priority to KR1020237017457A priority Critical patent/KR102667828B1/ko
Publication of KR20190043630A publication Critical patent/KR20190043630A/ko
Application granted granted Critical
Publication of KR102537340B1 publication Critical patent/KR102537340B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0834—Compounds having one or more O-Si linkage
    • C07F7/0892—Compounds with a Si-O-N linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
KR1020197010376A 2016-09-16 2017-09-15 베타-락타마제 억제제 화합물 Active KR102537340B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237017457A KR102667828B1 (ko) 2016-09-16 2017-09-15 베타-락타마제 억제제 화합물

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662395464P 2016-09-16 2016-09-16
US62/395,464 2016-09-16
US201762456423P 2017-02-08 2017-02-08
US62/456,423 2017-02-08
PCT/US2017/051692 WO2018053215A1 (en) 2016-09-16 2017-09-15 Beta-lactamase inhibitor compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237017457A Division KR102667828B1 (ko) 2016-09-16 2017-09-15 베타-락타마제 억제제 화합물

Publications (2)

Publication Number Publication Date
KR20190043630A KR20190043630A (ko) 2019-04-26
KR102537340B1 true KR102537340B1 (ko) 2023-05-26

Family

ID=60083416

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197010376A Active KR102537340B1 (ko) 2016-09-16 2017-09-15 베타-락타마제 억제제 화합물
KR1020237017457A Active KR102667828B1 (ko) 2016-09-16 2017-09-15 베타-락타마제 억제제 화합물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237017457A Active KR102667828B1 (ko) 2016-09-16 2017-09-15 베타-락타마제 억제제 화합물

Country Status (24)

Country Link
US (1) US10800778B2 (cg-RX-API-DMAC7.html)
EP (1) EP3512851B1 (cg-RX-API-DMAC7.html)
JP (2) JP6997178B2 (cg-RX-API-DMAC7.html)
KR (2) KR102537340B1 (cg-RX-API-DMAC7.html)
CN (2) CN109715630B (cg-RX-API-DMAC7.html)
AU (1) AU2017325863B2 (cg-RX-API-DMAC7.html)
CA (2) CA3036557A1 (cg-RX-API-DMAC7.html)
CY (1) CY1125826T1 (cg-RX-API-DMAC7.html)
DK (1) DK3512851T3 (cg-RX-API-DMAC7.html)
ES (1) ES2927986T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20221217T1 (cg-RX-API-DMAC7.html)
HU (1) HUE060282T2 (cg-RX-API-DMAC7.html)
IL (2) IL289686B2 (cg-RX-API-DMAC7.html)
LT (1) LT3512851T (cg-RX-API-DMAC7.html)
MA (1) MA46242A (cg-RX-API-DMAC7.html)
MX (2) MX392515B (cg-RX-API-DMAC7.html)
PH (1) PH12019500558B1 (cg-RX-API-DMAC7.html)
PL (1) PL3512851T3 (cg-RX-API-DMAC7.html)
PT (1) PT3512851T (cg-RX-API-DMAC7.html)
SG (1) SG11201901658PA (cg-RX-API-DMAC7.html)
SI (1) SI3512851T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200397T1 (cg-RX-API-DMAC7.html)
TW (1) TWI773687B (cg-RX-API-DMAC7.html)
WO (1) WO2018053215A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017290060B2 (en) 2016-06-30 2021-07-22 Qpex Biopharma, Inc Boronic acid derivatives and therapeutic uses thereof
SG11201901658PA (en) * 2016-09-16 2019-04-29 Entasis Therapeutics Ltd Beta-lactamase inhibitor compounds
PT3630111T (pt) 2017-05-08 2022-03-01 Entasis Therapeutics Inc Compostos e métodos de tratamento de infeções bacterianas
CN112424209A (zh) 2018-04-20 2021-02-26 Qpex生物制药有限公司 硼酸衍生物及其治疗用途
EP4272831A3 (en) 2018-08-09 2024-02-21 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
US12636297B2 (en) 2019-06-19 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
CN112209928B (zh) * 2019-07-10 2023-02-17 华东理工大学 共价键标记丝氨酸类beta-内酰胺酶的试剂及制备和应用
CN110898999A (zh) * 2019-11-26 2020-03-24 中国矿业大学 一种煤焦油基煤泥浮选药剂及其制备方法
US12637481B2 (en) 2020-03-18 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
IL297458A (en) 2020-05-05 2022-12-01 Qpex Biopharma Inc Boronic acid derivatives and their synthesis, polymorphic forms and medicinal uses
CN111790439B (zh) * 2020-07-29 2022-12-27 成都能特科技发展有限公司 一种手性二级胺二苯基膦芳甲酰胺双功能催化剂及其制备方法与应用
WO2022047603A1 (en) 2020-09-01 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Beta-lactamase inhibitors and their preparation
EP4319760A4 (en) * 2021-04-05 2025-01-08 Qpex Biopharma, Inc. CEFTIBUTENE DOSAGE REGIMEN
US12410166B2 (en) 2021-05-07 2025-09-09 Ningxia Academy Of Agriculture And Forestry Sciences Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors
US11814385B2 (en) 2021-06-25 2023-11-14 University Of South Florida Small molecule inhibitors targeting Clostridioides difficile sporulation
WO2023206580A1 (en) 2022-04-29 2023-11-02 Entasis Therapeutics Limited Durlobactam crystalline forms
US20230398101A1 (en) * 2022-06-09 2023-12-14 Fleurir Abx Llc Co-agents as Therapy Against Anaerobic Pathogens
CN118271319B (zh) * 2022-12-30 2025-02-28 成都四面体药物研究有限公司 一种β-内酰胺酶抑制剂含脲双环化合物、其制备方法及其用途
CN118772145B (zh) * 2023-04-04 2025-10-10 上海医药工业研究院有限公司 一种二氮杂双环辛烯化合物的制备方法
CN116693531A (zh) * 2023-06-09 2023-09-05 河南师范大学 一种桥联多环内酰胺类化合物的合成方法
WO2025106662A1 (en) * 2023-11-15 2025-05-22 Entasis Therapeutics, Inc. Preparation of boronic acid intermediates useful for the preparation of compounds for treating bacterial infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110046102A1 (en) 2008-04-29 2011-02-24 Novexel Azabicyclic compounds, preparation thereof and use of same as drugs, especially beta-lactamase inhibitors
WO2013030733A1 (en) 2011-08-27 2013-03-07 Wockhardt Limited 1,6- diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
WO2013150296A1 (en) * 2012-04-02 2013-10-10 Astrazeneca Ab Heterobicyclic compounds as beta-lactamase inhibitors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4607041A (en) * 1983-04-27 1986-08-19 Fisons Plc Antihypertensive 2-phenyl Hantzsch dihydropyridines
ATE177099T1 (de) 1993-12-29 1999-03-15 Pfizer Diazabicyclische neurokinin antagonisten
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2848210B1 (fr) 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
JP5038509B2 (ja) * 2008-01-18 2012-10-03 メルク・シャープ・エンド・ドーム・コーポレイション β−ラクタマーゼ阻害剤
EP2921559A1 (en) 2008-06-19 2015-09-23 Astra Zeneca Holding France Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2937034B1 (fr) 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
RS59255B1 (sr) * 2010-04-20 2019-10-31 Fujifilm Toyama Chemical Co Ltd Derivat hidroksaminske kiseline
EP2768503A1 (en) 2011-07-26 2014-08-27 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
CA2842777C (en) 2011-07-26 2015-12-29 Wockhardt Limited Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
CN103649088B (zh) 2011-08-30 2016-05-11 沃克哈特有限公司 1, 6- 二氮杂双环[3, 2, 1]辛- 7- 酮衍生物及其在治疗细菌感染中的用途
BR112014003476A2 (pt) 2011-09-13 2017-03-01 Wockhardt Ltd compostos contendo nitrogênio e seu uso
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
EP2814483A2 (en) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
JP2015512419A (ja) 2012-03-30 2015-04-27 キュービスト ファーマシューティカルズ, インコーポレイテッド イソオキザゾールβ−ラクタマーゼ阻害剤
TW201343645A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc 1,3,4-□二唑及1,3,4-噻二唑β-內醯胺酶抑制劑
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
HUE046893T2 (hu) 2012-05-30 2020-04-28 Meiji Seika Pharma Co Ltd Új ß-laktamáz inhibitor és eljárás elõállítására
ES2672100T3 (es) 2012-08-25 2018-06-12 Wockhardt Limited Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona y su uso en el tratamiento de infecciones bacterianas
NZ706734A (en) 2012-09-03 2016-05-27 Wockhardt Ltd Pharmaceutical compositions useful for the treatment or control of bacterial infections
CN104994860A (zh) 2013-02-06 2015-10-21 阿斯利康(瑞典)有限公司 用于治疗医院性肺炎的组合疗法
WO2014141132A1 (en) 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
TWI690317B (zh) * 2014-11-17 2020-04-11 英商安特西醫療有限公司 用於治療抗藥性細菌感染之組合療法
CA2980085A1 (en) * 2015-03-31 2016-10-06 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections
SG11201901658PA (en) * 2016-09-16 2019-04-29 Entasis Therapeutics Ltd Beta-lactamase inhibitor compounds
KR20230007830A (ko) * 2021-07-06 2023-01-13 현대자동차주식회사 고강성 저선팽창 열가소성 수지 조성물 및 이를 포함하는 성형체

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110046102A1 (en) 2008-04-29 2011-02-24 Novexel Azabicyclic compounds, preparation thereof and use of same as drugs, especially beta-lactamase inhibitors
WO2013030733A1 (en) 2011-08-27 2013-03-07 Wockhardt Limited 1,6- diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
WO2013150296A1 (en) * 2012-04-02 2013-10-10 Astrazeneca Ab Heterobicyclic compounds as beta-lactamase inhibitors

Also Published As

Publication number Publication date
SI3512851T1 (sl) 2022-11-30
AU2017325863B2 (en) 2021-08-19
WO2018053215A1 (en) 2018-03-22
AU2017325863A1 (en) 2019-03-14
IL289686B (en) 2022-11-01
PH12019500558B1 (en) 2023-09-08
PL3512851T3 (pl) 2022-11-14
IL265276B (en) 2022-02-01
JP6997178B2 (ja) 2022-02-03
IL289686B2 (en) 2023-03-01
US10800778B2 (en) 2020-10-13
EP3512851A1 (en) 2019-07-24
NZ751016A (en) 2025-02-28
KR20190043630A (ko) 2019-04-26
SMT202200397T1 (it) 2022-11-18
IL265276A (en) 2019-05-30
JP7281527B2 (ja) 2023-05-25
HRP20221217T1 (hr) 2022-12-23
MX385507B (es) 2025-03-18
CN109715630A (zh) 2019-05-03
MX2019003060A (es) 2019-07-08
JP2022046563A (ja) 2022-03-23
IL289686A (en) 2022-03-01
CA3036557A1 (en) 2018-03-22
MA46242A (fr) 2019-07-24
TW201823207A (zh) 2018-07-01
PT3512851T (pt) 2022-10-11
PH12019500558A1 (en) 2019-07-29
LT3512851T (lt) 2022-10-25
CN114591223B (zh) 2025-01-24
MX392515B (es) 2025-03-24
HUE060282T2 (hu) 2023-02-28
US20190202832A1 (en) 2019-07-04
CN109715630B (zh) 2022-02-22
DK3512851T3 (en) 2022-10-17
ES2927986T3 (es) 2022-11-14
EP3512851B1 (en) 2022-07-06
MX2021010077A (es) 2022-05-23
KR20230078830A (ko) 2023-06-02
CY1125826T1 (el) 2026-02-25
KR102667828B1 (ko) 2024-05-20
BR112019005053A2 (pt) 2019-06-18
TWI773687B (zh) 2022-08-11
SG11201901658PA (en) 2019-04-29
JP2019532928A (ja) 2019-11-14
CA3314454A1 (en) 2026-08-05
CN114591223A (zh) 2022-06-07

Similar Documents

Publication Publication Date Title
JP7281527B2 (ja) ベータラクタマーゼ阻害剤化合物
TWI597281B (zh) β-內醯胺酶抑制劑化合物
JP7598594B2 (ja) オキソ置換化合物
RU2741496C2 (ru) Гетероциклические соединения и их применение в лечении или предотвращении бактериальных инфекций
JP7589139B2 (ja) 複素環式化合物及び細菌感染の予防又は治療へのそれらの使用
JP7550421B2 (ja) オキソ置換化合物からなる医薬
HK40011101A (en) Beta-lactamase inhibitor compounds
HK40011101B (en) Beta-lactamase inhibitor compounds
EA044428B1 (ru) Соединения-ингибиторы бета-лактамаз
EA037916B1 (ru) Соединения-ингибиторы бета-лактамаз
BR112019005053B1 (pt) Compostos inibidores de beta-lactamase, usos dos mesmos, composição farmacêutica, e processo para formação de um composto
NZ791470A (en) Beta-lactamase inhibitor compounds

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4